VIDEO: 'Exciting time' for development of oral selective estrogen degraders
Click Here to Manage Email Alerts
In this video, Sara Hurvitz, MD, discussed recent developments in oral selective estrogen degraders reviewed at 39th Miami Breast Cancer Conference.
"It's a really exciting time right now with data just emerging relating to how the oral [selective estrogen degraders (SERDs)] work compared to standard of endocrine therapy," said Hurvitz, an associate professor at David Geffen School of Medicine at UCLA and medical director of Jonsson Comprehensive Cancer Center Clinical Research Unit.
Results from the EMERALD trial, a multicenter, international, randomized, open-label, controlled phase 3 trial evaluating elacestrant as a monotherapy vs. standard of care for the treatment of ER-positive/HER2-negative advanced or metastatic breast cancer, which were presented at the San Antonio Breast Cancer Symposium in December, were discussed as part of the plenary session.
Hurvitz said the results showed “for the first time in a randomized clinical trial that an oral SERD beat out standard endocrine therapy, in this case elacestrant."
Collapse
Read more about
Click Here to Manage Email Alerts